Skip to content
KPTIQKaryopharm Therapeutics Inc.

Earnings

When Karyopharm Therapeutics Inc. reports, what it reported each quarter, and how the stock took the results.

58 quarters. Mar 31, 2012 to Jun 30, 2026. USD.

Next results · Q3 2026Window passed

No 10-Q yet

Mon, Nov 2, 202615 days ago

The 10-Q window, Nov 2 – 16, passed with no filing on file.

Quarter
Q3 2026 · Ended Sep 30, 2026
10-Q window
Nov 2 – 16

Read against Q3 2025

The same quarter a year earlier, the figures the next ones will be compared with. Thaler holds no estimates.

Revenue
$44.04M
Revenue, change from a year earlier: Q2 2026 −11.9%, Q1 2026 +16.8%, Q4 2025 +11.6%, Q3 2025 +13.6%
Net income
-$33.13M
Net income, change from a year earlier: Q2 2026 n/m, Q1 2026 n/m, Q4 2025 n/m, Q3 2025 n/m
EPS
-$3.82
EPS, change from a year earlier: Q2 2026 n/m, Q1 2026 n/m, Q3 2025 n/m, Q2 2025 n/m

Quarter by quarter

Q2 2026$33.43M−11.9% vs Q2 2025

Latest results

  1. Q2 2026Aug 13, 2026, before the openThe release
    Revenue
    $33.43M
    −11.9%
    Net income
    -$67.02M
    N/M
    EPS
    -$2.32
    N/M
  2. Q1 2026May 14, 2026, before the openThe release
    Revenue
    $35.07M
    +16.8%
    Net income
    -$22.39M
    N/M
    EPS
    -$1.24
    N/M
  3. Q4 2025Feb 12, 2026, before the openThe release
    Revenue
    $34.08M
    +11.6%
    Net income
    -$102.20M
    N/M
    EPS
    —
    —
  4. Q3 2025Nov 3, 2025, before the openThe release
    Revenue
    $44.04M
    +13.6%
    Net income
    -$33.13M
    N/M
    EPS
    -$3.82
    N/M

All quarters

PeriodEndedAnnouncedFiledLagFormRevenueΔ yoyEPS dil.MoveSource trail
FY 2026
Q2 2026Jun 30, 2026Aug 13, 2026 · pre-marketAug 13, 202644 d10-Q$33.43M−11.9%-$2.32—
Q1 2026Mar 31, 2026May 14, 2026 · pre-marketMay 14, 202644 d10-Q$35.07M+16.8%-$1.24—
FY 2025
Q4 2025derivedDec 31, 2025Feb 12, 2026 · pre-marketFeb 13, 202644 d10-K$34.08M+11.6%——
Q3 2025Sep 30, 2025Nov 3, 2025 · pre-marketNov 3, 202534 d10-Q$44.04M+13.6%-$3.82—
Q2 2025Jun 30, 2025Aug 11, 2025 · pre-marketAug 11, 202542 d10-Q$37.93M−11.4%-$4.32—
Q1 2025Mar 31, 2025May 12, 2025 · after-hoursMay 12, 202542 d10-Q$30.02M−9.4%-$2.77—
FY 2024
Q4 2024derivedDec 31, 2024Feb 19, 2025 · pre-marketFeb 19, 202550 d10-K$30.54M−9.5%——
Q3 2024Sep 30, 2024Nov 5, 2024 · pre-marketNov 5, 202436 d10-Q$38.78M+7.7%-$3.85—
Q2 2024Jun 30, 2024Aug 6, 2024 · pre-marketAug 6, 202437 d10-Q$42.79M+13.9%-$2.97—
Q1 2024Mar 31, 2024May 8, 2024 · pre-marketMay 8, 202438 d10-Q$33.13M−14.4%-$4.85—
Earlier years, FY 2012 to FY 2023

Source filings

10-QAug 13, 2026347906
10-QMay 14, 2026222827
10-KFeb 13, 2026049397
10-QNov 3, 2025261667
10-QAug 11, 2025106238
10-QMay 12, 2025069231
10-KFeb 19, 2025022765
10-QNov 5, 2024121076
10-QAug 6, 2024091210
10-QMay 8, 2024055672

Provenance

ProvenanceData status and checks

Karyopharm Therapeutics Inc. · CIK 1503802 · Engraved from SEC EDGAR